CRSP vs NTLA
CRSP and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $4.97B | $1.75B |
| P/S | 1415.8x | 25.8x |
| Revenue growth (YoY) | -90.6% | 16.9% |
| Earnings growth (YoY) | -58.8% | 20.5% |
| EBIT margin | -18933.6% | -651.7% |
| ROE | -33.3% | -56.7% |
| ROIC | -32.6% | — |
| 1y total return | -15.9% | +1.6% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: CRSP frente a NTLA
| Métrica | CRSP | NTLA |
|---|---|---|
| Valor final | $36.5K | $9.9K |
| Retorno total | +264.9% | -1.1% |
| CAGR | +13.8% | -0.1% |
| Volatilidad | 63.9% | 78.4% |
| Sharpe | 0.45 | 0.34 |
| Sortino | 0.70 | 0.50 |
| Caída máxima | -85.1% | -96.5% |
Basado en 2522 días de negociación comunes, 2016-10-19 → 2026-10-30 · tasa libre de riesgo 4.16% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)